1 Section of Cardiovascular Medicine Department of Medicine Boston Medical Center Boston University School of Medicine Boston MA.
4 Division of Cardiovascular Medicine Beth Israel Deaconess Medical Center Boston MA.
J Am Heart Assoc. 2019 Mar 19;8(6):e010976. doi: 10.1161/JAHA.118.010976.
Background Prior studies relating proteomics markers to incident AF screened for limited numbers of proteins. Methods and Results We performed proteomics assays among participants from the Framingham Heart Study Offspring attending their fifth examination. Plasma protein levels (n=1373) were measured by the SOMAscan proteomic profiling platform. We used robust inference for the Cox proportional hazards model to relate each protein level with incident AF. In addition, we examined the association between AF-related genetic loci and levels of proteins associated with AF. Our study included 1885 participants (mean age 55±10 years, 54% women) who had proteomic profiles measured. A total of 349 participants developed AF during follow-up (mean follow-up 18.3 years). We observed that 8 proteins were significantly associated with incident AF after adjusting for age, sex, technical covariates, and correction for multiple testing ( P<0.05/1373=3.6×10). After additional adjustments for clinical factors associated with AF, ADAMTS13 and N-terminal pro-B-type natriuretic peptide remained significantly associated with the risk of incident AF (hazard ratio, 0.78; 95% CI, 0.70-0.88; and 1.44; 95% CI, 1.22-1.70, respectively; P<3.6×10 for both). None of the 8 proteins were encoded by genes at AF-related genetic loci previously identified by genome-wide association studies. Conclusions We identified 8 proteins associated with risk of incident AF after adjustment for age and sex; 2 proteins were associated with AF after adjustment for AF risk factors. Future studies are needed to replicate our findings, identify whether the markers are mechanistically related to AF development, and whether they are clinically useful for identification of future AF risk.
先前与房颤(AF)相关的蛋白质组学标志物研究筛选的蛋白质数量有限。
我们在参加弗雷明汉心脏研究后代第五次检查的参与者中进行了蛋白质组学检测。通过 SOMAscan 蛋白质组学分析平台测量血浆蛋白水平(n=1373)。我们使用稳健推理 Cox 比例风险模型将每种蛋白质水平与房颤的发生相关联。此外,我们还研究了房颤相关遗传位点与与房颤相关的蛋白质水平之间的关联。我们的研究包括 1885 名参与者(平均年龄 55±10 岁,54%为女性),他们的蛋白质组学特征得到了测量。在随访期间共有 349 名参与者发生房颤(平均随访 18.3 年)。我们发现,在调整年龄、性别、技术协变量和多重检验校正后,共有 8 种蛋白质与房颤的发生显著相关( P<0.05/1373=3.6×10)。在进一步调整与房颤相关的临床因素后,ADAMTS13 和 N 末端 pro-B 型利钠肽仍与房颤的发生风险显著相关(风险比,0.78;95%置信区间,0.70-0.88;和 1.44;95%置信区间,1.22-1.70;两者均 P<3.6×10)。这 8 种蛋白质均不由先前全基因组关联研究确定的房颤相关遗传位点编码。
在调整年龄和性别后,我们确定了 8 种与房颤发生风险相关的蛋白质;在调整房颤危险因素后,有 2 种蛋白质与房颤相关。需要进一步的研究来复制我们的发现,确定这些标志物是否与房颤的发生机制相关,以及它们是否对识别未来的房颤风险具有临床意义。